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Background
A prognostic index based on widely available clinical and laboratory features was recently pro-
posed to predict survival in patients with previously untreated chronic lymphocytic leukemia.
We assessed the utility of this index for predicting time to first treatment in early chronic lym-
phocytic leukemia.
Design and Methods
An observational database of the GIMEMA (Gruppo Italiano Malattie EMatologiche dell’Adulto),
which included 310 patients with newly diagnosed Binet stage A chronic lymphocytic
leukemia who were observed at different primary hematology centers during the period 1991
– 2000, was used for the purpose of this study.
Results
The new prognostic index enabled Binet stage A patients to be divided into two subgroups that
differed with respect to time to first treatment (P=0.003). The original prognostic index was
derived from a database that included cases observed at a reference academic center; these
patients were younger (P<0.0001) and had more advanced disease (P<0.0001) than those in the
current investigation, which studied community-based patients whose data were recorded at
presentation. With this in mind, we used an optimal cut-off search to determine how best to
split patients with Binet stage A disease into different prognostic groups. According to the
recursive partitioning (RPART) model, a classification tree was built that identified three sub-
sets of patients who scores were 0-2 (low risk), 3-4 (intermediate risk) and 5-7 (high risk). The
probability of remaining free from therapy at 5 years was 100% in the low risk group, 81.2%
in the intermediate risk group and 61.3% in the high risk group (P<0.0001). 
Conclusions
The results of this study confirm the utility of a new prognostic index for predicting time to
first treatment in a large sample series of community-based patients with early stage chronic
lymphocytic leukemia at presentation. Our effort to develop a revised scoring method meets
the need to separate Binet stage A patients into different prognostic groups in order to devise
individualized and tailored follow-up during the treatment-free period.
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Introduction
In parallel with significant improvements in treatment
outcome, there has been dramatic progress in the under-
standing of the biology of chronic lymphocytic leukemia
(CLL) and a number of new prognostic factors have been
identified.1 Although there is strong evidence linking prog-
nosis with biological markers, it is by no means defined
how these factors should be used in the management of
patients with CLL. In addition, before being incorporated
into daily practice these markers must be standardized and
validated in large prospective trials.2
The staging systems defined by Rai et al.3 and Binet et al.4
were based on their prognostic significance and the stage of
disease still remains the most important prognostic indica-
tor in CLL. However, clinical staging systems were devel-
oped in the late 1970s and over the years stage of disease
has lost some of its usefulness, since most patients are now
being diagnosed in an early stage, reflecting a broader use of
routine blood evaluations.5-7 As a logical consequence, there
is still a need for a simple and reliable method of risk strat-
ification suitable for all patients with CLL.
In line with efforts that led to the development of reli-
able and widely available prognostic systems in multiple
myeloma and follicular lymphoma,8,9 Wierda et al.10 pro-
posed a new prognostic index for patients with CLL. The
model predicting overall survival was constructed using
six factors (i.e., age, absolute lymphocyte count, gender,
β2-microglobulin concentration, Rai clinical stage and
number of involved lymph node regions) that were inde-
pendently associated with patients’ survival.10 This new
prognostic index was recently validated in an independent
series of CLL patients observed at the Mayo Clinic.11
Furthermore, the utility of the index was extended by the
demonstration that its value was retained when applied to
Rai stage 0 patients, in whom it could be used to predict
time to treatment.11
In order to determine the utility of the score in predict-
ing the time to first treatment (TFT), we analyzed the
information contained in an observational CLL database
run by GIMEMA (Gruppo Italiano Malattie EMatologiche
dell’Adulto).12
Design and Methods
Patients
The GIMEMA CLL database includes information on previous-
ly untreated CLL patients in Binet stage A whose diagnosis was
immunologically confirmed (CD5+/SmIg weak) and who were
observed at different GIMEMA primary hematology centers dur-
ing the period 1991–2000. All patients were treated outside of ther-
apeutic protocols according to a ‘‘wait and see’’ policy. Overall,
data from 1158 patients from 25 centers were entered into a pre-
liminary working file. Twenty patients (1.7%) were excluded
because of inadequate follow-up.
Data management and analyses were performed in accordance
with the ethical guidelines of the GIMEMA Review Board and the
tenets of the Declaration of Helsinki. The study was also evaluat-
ed and approved by the ethical committee of the Pugliese-Ciaccio
Hospital, Catanzaro.
Information regarding five parameters, age, gender, Rai stage,
absolute peripheral blood lymphocytosis and number of lymph
node sites involved, was available for all 1158 patients, while β2-
microglobulin levels were available for only 310 patients. The
characteristics of the five former parameters were, however, the
same for patients with and without β2-microglobulin data. This
was also the case when the probability of remaining free from
therapy at 5 years was evaluated for patients with and without
available β2-microglobulin data (80% versus 78%, respectively;
P=0.07).
Indication for therapy
Active, therapy-requiring disease was defined by the presence
of at least one of the following criteria:13 (i) evidence of progres-
sive marrow failure, manifested by the development or worsen-
ing of anemia and/or thrombocytopenia; (ii) massive (i.e., >6 cm
below the left costal margin) or progressive or symptomatic
splenomegaly; (iii) massive lymph nodes (i.e., >10 cm in the
longest diameter) or progressive or symptomatic lymphadenopa-
thy; (iv) progressive lymphocytosis with an increase of more than
50% over a 2-month period, or a lymphocyte doubling time
(LDT) of less than 6 months; (v) autoimmune anemia and/or
thrombocytopenia poorly responsive to corticosteroids or other
standard therapy; and (vi) unintentional weight loss of 10% or
more within the previous 6 months or significant fatigue (i.e.,
Eastern Cooperative Oncology Group Performance Score of 2 or
worse; unable to work or to perform usual activities) or fever
higher than 38.0°C for 2 or more weeks without other evidence
of infections or night sweats for more than 1 month without evi-
dence of infection. 
The absolute lymphocyte count was not used as the sole indica-
tor for treatment.
Nomogram and prognostic index scores
Age, gender, absolute lymphocyte count, β2-microglobulin, Rai
stage and number of lymph node regions involved were used to
calculate the prognostic index score according to the method pro-
posed by Wierda et al.10 Since only Binet stage A patients were
included, Rai substages were dichotomized as follows: Rai 0 ver-
sus Rai I-II (Table 1). 
The nomogram score was also calculated using the published
formula:
Total score = -12.5 + [1.25 x age] + [4.32 x β2-microglobulin] +
[8.62 x (absolute lymphocyte count ×109/L/100)] + [7.34 × I (sex =
male)] + [11.00 × I (Rai stage = III or IV)] + [10.84 × I (lymph nodes
= 3)], where I is the indicator function equal to 1 if the condition in
parenthesis is met and 0 if not.
Statistical analysis
Estimates of TFT were calculated using the Kaplan-Meier
method. Likelihood ratio tests were used to analyze the effects of
individual factors, either univariately or jointly. Hazard ratios (HR)
and confidence intervals (CI) for these ratios were calculated from
the Cox models. In both univariate and multivariate analysis con-
tinuous variables such as age, absolute lymphocyte count and β2-
microglobulin were stratified, as proposed by Wierda et al.,10 as
follows: (i) age (years): less than 50, 50-65, more than 65; (ii)
absolute lymphocyte count (×109/L): less than 20, 20-50, more than
50; c) β2-microglobulin (mg/L): less than the upper limit of normal
(ULN)(i.e., 1.8 mg/L), 1-2 times the ULN, more than two times the
ULN. The recursive partitioning (RPART) model was used to
search for appropriate cut-off points of the score of the prognostic
index and to determine how best to split patients in Binet stage A
into different subgroups.
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Results
Patients’ characteristics
The main characteristics of the 310 stage A patients for
whom complete data were available for the six parame-
ters used to calculate the newly proposed index score are
shown in Table 2. The male to female ratio was 1.27 and
the median age at diagnosis was 64 years, with 49% of
patients aged more than 65 years and 30.3% aged more
than 70 years. The majority of patients had Rai stage 0 dis-
ease (67%) and virtually all were local, non-referred
patients, first diagnosed and then managed at different pri-
mary Italian hematology centers. The 310 patients were
followed for a total of 1,303 person-years (median, 41.5
months; range, 3-199 months) during which 51 required
therapy. The probability of remaining free from therapy
was 78.8% at 5 years and 59% at 10 years, with no
plateau reached (Figure 1).
Individual factors and multivariate time to first 
treatment analysis
The correlation between the six factors included in the
prognostic score described by Wierda et al.10 and the TFT
is presented in Table 3. Among the baseline factors evalu-
ated with respect to TFT, the following were associated
with a more unfavorable clinical outcome: male gender
(P=0.007), increased concentration of β2-microglobulin
(P=0.0008), Rai substage I-II (P=0.02) and higher absolute
lymphocyte count (P=0.0007). Associations were not
found for age (P=0.97) and number of involved lymph
node groups (P=0.68). 
Multivariate regression analysis was carried out to assess
the relationship between independent variables and TFT in
a Cox proportional hazards model. Gender (P=0.01), β2-
microglobulin level (P=0.002) and absolute lymphocyte
count (P=0.01) were found to be independently associated
with TFT in this analysis (Table 4). Interestingly, the haz-
ard ratio higher than 2 found for all these variables quali-
fies the analysis as highly discriminating.
Nomogram score
For each patient we calculated the nomogram score
using the formula proposed by Wierda et al.10 The median
nomogram score for the 310 Binet stage A patients was 80
(range, 34-120), which was similar to the median score
reported by both the M.D. Anderson Cancer Center
(median, 82.9) and the Mayo Clinic (median, 83.9). The
median nomogram score enabled the patients to be strati-
fied into two groups with different TFT (χ2=18.73;
P<0.0001; HR=3.95; 95% CI, 3.95-5.47) (Figure 2).
M.D. Anderson Cancer Center prognostic index score
Using the method proposed by Wierda et al.,10 we calcu-
lated the prognostic index score for the 310 Binet stage A
patients. Given the cohort of patients considered in this
study (i.e., all with Binet stage A disease), no patient had
a score higher than 7, necessary for inclusion in the high-
risk group. Therefore, according to the prognostic index,
47% of patients met the criteria for low risk (score 0-3)
and 53% the criteria for intermediate risk (score 4-7).
The new prognostic index enabled the Binet stage A
patients to be divided into two subgroups that differed
with respect to TFT. The estimated median TFT was not
reached for the low risk group, while it was 111 months
for patients in the intermediate risk category (χ2=8.50;
P=0.003; HR= 2.38; 95% CI, 1.29-3.72) (Figure 3). Even
though our focus was the TFT, the index scores of our
cohort were related to overall survival. The actuarial sur-
vival probability at 5 years was 99.3% and 88.2% for
patients who scored 0-3 and 4-7, respectively (P=0.0005).
Since the stratification according to the Rai system, used
as a comparison, showed a lower discriminating power
S Molica et al.
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Table 1. Prognostic index based on the presence of risk factors.
Characteristic Point contribution
0 1 2 3 
Age, years − < 50 50-65 > 65
β2M, mg/L < ULN 1-2 x ULN > 2 x ULN −
ALC, ×109/L < 20 20-50 > 50 −
Gender Female Male − −
Rai stage* 0 I-II − −
N. of involved 0-2 ≥3 − −
nodal groups 
β2M: β2-microglobulin; ULN: upper limit of normal;ALC: absolute lymphocyte count.The
patient’s total score was obtained by adding up the scores for the six components.
Adapted from Wierda et al.10 *Since only Binet stage A patients were included in this
analysis,Rai substages were dichotomized as follows: Rai 0 versus Rai I-II.
Table 2. Patients’ characteristics (n = 310).
Characteristic Number (%)
Age at diagnosis (years)
<50 27 (8.7)
50-69 77 (24.8)
60-69 111 (35.8)
70-79 78 (25.1)
> 80 17 (5.4)
Gender 
Male 174 (56.1)
Female 136 (43.8)
Rai stage at diagnosis
0 208 (67)
I-II 102 (32.9)
Absolute lymphocyte count (×109/L)
< 20 245 (78)
20-50 54 (17.4) 
> 50 11 (3.5)
Serum β2-microglobulin (mg/L)
< ULN*  157 (50.6) 
1-2 x ULN 132 (42.5) 
>2 x ULN 11 (3.5)
Number of lymph node sites involved
0-2 290 (93.5)
3 or more 20 (6.4)
*ULN indicates upper limit of normal (i.e., 1.8 mg/L).
(χ2=4.22; P=0.03; HR=1.86; 95% CI, 1.02-3.21), we won-
dered whether the new prognostic index could add prog-
nostic information to that afforded by Rai staging. All
patients in Rai stage I-II fulfilled the criteria for an interme-
diate risk score according to Wierda et al.10 and were,
therefore, considered not suitable for this analysis. As far
as concerns Rai stage 0, differences in TFT were observed
among patients according to whether they were classified
as being at low or intermediate risk by the prognostic
index (χ2=18.80; P<0.0001; HR=2.79; 95% CI, 3.92-37.4).
The prognostic index proposed by Wierda et al.10 was
originally derived from a database collecting information
on CLL patients observed at a reference academic center;
these patients had more advanced disease (P<0.0001) and
were younger (P<0.0001) than our cohort of patients
(Table 5). With this in mind, we wondered whether differ-
ent cut-off scores would predict patients’ TFT better in the
GIMEMA series, which consisted of local, non-referred
patients with early disease studied at presentation. We,
therefore, applied an optimal cut-off score search to deter-
mine how best to split Binet stage A patients into different
subgroups. According to the RPART model, we were able
to build a classification tree that identified three subsets of
patients who scores were: 0-2 (low risk), 3-4 (intermediate
risk) and 5-7 (high risk) (Figure 4). When applied to our set
of Binet stage A patients, the modified prognostic score
documented a clear-cut separation between different
groups. As shown in Figure 5, the probability of remaining
free from therapy at 5 years was 100% in the low risk
group, 81.2% in the intermediate risk group and 61.3% in
the high risk group (χ2 for trend=16.87; df=1; P<0.0001).
Discussion
Wierda et al.10 developed a prognostic index, based on
widely available clinical and laboratory features, to predict
survival among patients with previously untreated CLL.
The validity and reproducibility of this index was recent-
ly confirmed in an independent series of patients followed
at the Mayo Clinic.11 Our analysis based on an observa-
tional CLL multicenter database assessed the utility of the
prognostic index proposed by Wierda et al.10 to predict
TFT in patients with early disease.
Validation of a prognostic index in early CLL
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Figure 1. Kaplan-Meier estimate of the time to first treatment of
310 patients with Binet stage A CLL.
Figure 2. Kaplan-Meier estimate of the time to first treatment of
Binet stage A patients stratified according to the median value
obtained by the M.D. Anderson Cancer Center nomogram score.9
Figure 3. Kaplan-Meier estimate of the time to first treatment by
prognostic index category in patients with Binet stage A CLL.
Table 3. Univariate Cox proportional hazard model for time to first
treatment. 
Variable Hazard ratio 95% Confidence P value
interval 
Gender 2.25 1.23-4.11 0.007
Rai stage 0 vs I-II 1.89 1.07-3.33 0.02
Absolute lymphocyte 3.54 0.59-7.86 0.0009
count*
β2-microglobulin* 4.23 2.40-7.48 < 0.00001
Age* 0.60 0.20-3.40 0.97
N. lymph node groups 0.75 0.18-3.08 0.68
involved: ≤2 vs. ≥3
*The statistical analysis was carried out after stratifying patients, as proposed by
Wierda et al.10, into the following groups: (a) age (years): < 50,50-65,> 65; (b) absolute
lymphocyte count (109/L) : <20,20-50,>50; (c) β2-microglobulin (mg/L): < upper limit
of normal (ULN),1-2 ULN,> 2x ULN.
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Patients with nomogram score < 80
Patients with nomogram score > 80
Chi square=18.73;
df=1; P<0.0001
Chi square 8.508
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P value 0.0035
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The original prognostic index was derived from a data-
base that included data on CLL cases observed at a refer-
ence academic center; the patients, therefore, had more
advanced disease than our series, which consisted of com-
munity-based Binet stage A patients whose data were
recorded at presentation. These differences between the
cohorts of patients led to some revisions of the original
scoring system proposed by Wierda et al.10 Consequently,
we reassigned the points for disease stage according to Rai
et al.3 and the point groupings were reassessed on the basis
of a decision tree analysis.
This study was made possible by the fact that in Italy
patients with lymphocytosis are referred to hematology
centers.12 This allows a horizontal long-term observation-
al follow-up of patients with CLL from early diagnosis
that is representative of the natural course of the disease.
The same does not apply for the studies recently reported
by the two academic referral centers in the USA. In detail,
25% of the patients evaluated at the M.D. Anderson
Cancer Center received treatment within 60 days of first
observation, while 65.7% of patients evaluated at the
Mayo Clinic could be considered referred.10,11 Conse-
quently, different degrees of both lead and length time
bias affect the results of these previously published stud-
ies when time-related end-points such as overall survival
and TFT are evaluated.
Identifying prognostic factors and developing models
that predict clinical end-points are of great importance in
order to understand the disease better and to be able to
provide more accurate information to patients. Among the
end-points that can be studied in prognostic analyses, we
decided to measure outcome in terms of TFT, which
appears more suitable than overall survival for patients
with early CLL. TFT does not reflect competing risks
between successive relapses, histological transformation,
deaths in remission or the impact of new therapies.
Consequently, the fact that some of the variables in the
index do not correlate with TFT in univariate or multivari-
ate analyses does not mean that the associations reported
for these variables by the M.D. Anderson Cancer Center
do not hold. In fact, the original analysis reported exclu-
sively on overall survival with no data on TFT, while the
current analysis does the reverse.
Several paradigms of CLL have changed in the last 30
years. First of all, a shift toward diagnosis at an early stage
has now been recognized; accordingly, it is inappropriate
to reassure all patients with early-stage disease that they
should not be concerned about their disease.5-7 Patients
with early-stage CLL are a very heterogeneous population
S Molica et al.
468 haematologica | 2010; 95(3)
Figure 4. Classification tree built according to recursive partitioning
(RPART). The number of patients who required therapy in each
group is shown first and then the total number of patients. RR indi-
cates the relative risk.
Figure 5. Kaplan-Meier estimate of the time to first treatment of
Binet stage A patients. According to recursive partitioning (RPART)
analysis patients were segregated into three risk categories: low-risk
(score, 0-2), intermediate-risk (score, 3-4) and high-risk (score, 5-7).
Table 4. Multivariate Cox proportional hazard model for time to first
treatment.
Variable Hazard ratio 95% Confidence P value
Interval
Gender 2.23 1.22- 4.09 0.01
β2microglobulin 2.46 1.40-4.04 0.002
Absolute lymphocyte 3.09 1.39-6.87 0.006
count
Table 5. Comparison between demographic characteristics of the M.D.
Anderson Cancer Center (MDACC) series and the GIMEMA series.
MDACC series* GIMEMA series P value
Male/Female 1029/645 174/136 0.07
Age
<50 years 395 (23.5%) 28 (9.0%)
50-65 years 838 (50.0%) 143 (46.1%) <0.0001
> 65 years 441 (26.3%) 139 (44.8%)
Rai stage
0 469 (28.1%) 208 (67.0%) 
I-II 974 (58.3%) 102 (32.9%) <0.0001
III-IV 220 (11.9%) Not included
*Wierda et al.10
score ≤ 2
score 3-4
score 5-7Logrank test for trend
Chi square=16.87;
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with respect to clinical outcome,14 and risk stratification is,
therefore, particularly important in this subset of patients,
currently the most numerous, in order to provide individ-
ualised and tailored follow-up.
Recently identified prognostic factors - i.e., mutational
status of the IGVH gene regions, ZAP-70 or CD-38 expres-
sion, cytogenetic abnormalities, and p53 mutations - can
be used to stratify asymptomatic patients with early dis-
ease into low-risk, intermediate-risk and high-risk cate-
gories.14-21 As shown, in the present study the prognostic
index proposed by Wierda et al.,10 which is based on clini-
cal and basic laboratory characteristics, has proven to be a
powerful risk stratification system also for patients with
early CLL. Nonetheless, we believe that refinement of this
system, through the addition of molecular and biological
parameters, will contribute to improve its prognostic accu-
racy further.
In order to exclude a possible bias due to the fact that
β2-microglobulin values at the time of diagnosis were
available for only 310 of the 1158 patients, the overall
characteristics of the individual parameters included in the
score index, as well as TFT, were analyzed for patients
with and without available β2-microglobulin data and no
differences were observed.
Finally, our study has a number of important strengths.
The individuals studied were from a well-defined cohort
of CLL patients participating in observational trials. All
patients studied had early stage disease at the entry into
the study and thus represent the group of patients for
whom prognostic instruments are most needed.
Moreover, our effort to develop a revised scoring method
meets the need to separate Binet stage A patients into dif-
ferent prognostic groups, in order to devise individualized
and tailored follow-up during the treatment-free period.
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